NCT05064280: Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must haver 1 measurable brain metastasis; If patient had prior whole brain radiation therapy or SRS, progression in any measurable brain metastasis must have occurred at least 1 month after the end of radiation
Exclusions: Patients with clinical or radiographic evidence of leptomeningeal metastases; Patients who received prior therapy with lenvatinib or other tyrosine kinase inhibitor (e.g. lapatinib, neratinib) alone or in combination with a PD-1/PD-L1 inhibitor (e.g., Keytruda/pembrolizumab, Tecentriq/atezolizumab)

Comments are closed.

Up ↑